GlobeNewswire

Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
11/12/2025
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National Health Service MOUNTAIN VIEW [...]
Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board
11/12/2025
Strategic Appointment Aligns Business Growth with Mission to Deliver Equitable, Affordable Medicines SAN FRANCISCO and KIGALI, Rwanda, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Inc., a biotechnology company dedicated [...]
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
11/12/2025
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting [...]
Aukera Therapeutics Comes Out of Stealth
11/12/2025
David Urech to join the board BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters [...]
Immunovant Announces Pricing of $550 Million Common Stock Financing
11/12/2025
Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal [...]
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
11/12/2025
Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
11/12/2025
Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline [...]
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
11/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
11/12/2025
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants and [...]
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity
11/12/2025
Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, [...]
China Gold Irradiation adopte la technologie d'irradiation par rayons X d'IBA afin d'accroître ses capacités de production
11/12/2025
Louvain-la-Neuve, Belgique, le 11 décembre 2025 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et [...]
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
11/12/2025
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year [...]
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
10/12/2025
Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 [...]
Bioxodes lève 5,5 millions d'euros dans le cadre d'une extension de la Série A afin de poursuivre la préparation d’un essai pivot pour son candidat-médicament innovant dans le traitement de l'AVC
10/12/2025
Newton Biocapital entre au capital en tant que nouvel investisseur, importante participation des investisseurs historiques Lancement en 2027 d’un essai pivot de phase 2b portant sur BIOX-101 dans le traitement de l’AVC [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10/12/2025
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile pharma collaboration [...]
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
10/12/2025
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population [...]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price [...]
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
10/12/2025
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Terns Announces Pricing of Upsized $650 Million Public Offering
10/12/2025
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum